UK markets closed

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.8600-0.0400 (-1.03%)
At close: 4:00PM EDT
3.8601 0.00 (0.00%)
After hours: 04:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.9000
Open3.9100
Bid3.7700 x 900
Ask3.9500 x 1800
Day's range3.6700 - 3.9500
52-week range3.6700 - 10.9300
Volume1,793,643
Avg. volume931,917
Market cap600.218M
Beta (5Y monthly)2.18
PE ratio (TTM)N/A
EPS (TTM)-0.9290
Earnings date04 Aug 2021 - 09 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.29
  • 2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin
    Motley Fool

    2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin

    Dogecoin (CRYPTO: DOGE), in many ways, is at the epicenter of the cryptocurrency craze. In fact, Dogecoin's price has fallen by more than 58% from its recent highs, implying that the rampant enthusiasm that drove the coin's price through the roof earlier this year may be waning, perhaps for good. The good news is that there are a handful of biotech penny stocks (equities with a sub-$5 share price) capable of delivering jaw-dropping returns for risk-tolerant investors.

  • Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
    Simply Wall St.

    Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • Why Adaptimmune Therapeutics Crushed the Market Today
    Motley Fool

    Why Adaptimmune Therapeutics Crushed the Market Today

    Adaptimmune Therapeutics (NASDAQ: ADAP), a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. In advance of a June industry congress, Adaptimmune unveiled the results of its SPEARHEAD-1 study. This was undertaken to gauge the efficacy of its afamitresgene autoleucel, or afami-cel, to treat synovial sarcoma (cancer of soft tissue such as muscles or ligaments) and myxoid/round cell liposarcoma (MRCLS; a cancer of the cells that store fat).